- Crizotinib (CAS 877399-52-5) is a high-purity anticancer API, a targeted tyrosine kinase inhibitor (TKI) designed to treat ALK/ROS1-positive non-small cell lung cancer (NSCLC). Its precise molecular structure enables specific binding to abnormal ALK/ROS1 kinases, blocking tumor cell proliferation and signaling pathways.
- Produced under strict GMP standards, this API ensures high purity and consistent bioactivity, meeting global pharmaceutical quality requirements. It is primarily used in formulating oral anticancer medications, suitable for patients with locally advanced or metastatic ALK/ROS1-positive NSCLC, effectively delaying tumor progression and improving quality of life.
Crizotinib (CAS 877399-52-5) Anticancer API
$3,000.00
Crizotinib (sold under the brand name Xalkori, among others) is a targeted cancer medication used to treat specific types of advanced non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumors (IMT).
Be the first to review “Crizotinib (CAS 877399-52-5) Anticancer API”
Reviews
There are no reviews yet.